{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/palliative-care-nausea-vomiting/management/known-cause/","result":{"pageContext":{"chapter":{"id":"e2566bf0-9d82-5bc7-9b5f-835384f56bc2","slug":"known-cause","fullItemName":"Scenario: Known cause","depth":2,"htmlHeader":"<!-- begin field f47f9f0a-952d-4d0d-a068-8a3ea72586f3 --><h2>Scenario: Known cause</h2><!-- end field f47f9f0a-952d-4d0d-a068-8a3ea72586f3 -->","summary":"Covers management of nausea and vomiting in palliative care when the cause is known. This scenario also covers treatment options when first-line anti-emetics have not worked.","htmlStringContent":"<!-- begin item fd1d33dc-c176-463d-af81-2255ed3a4660 --><!-- begin field b69d7a04-6784-49ee-b2ec-acbc015bbb34 --><p>From age 16 years onwards.</p><!-- end field b69d7a04-6784-49ee-b2ec-acbc015bbb34 --><!-- end item fd1d33dc-c176-463d-af81-2255ed3a4660 -->","topic":{"id":"8a2e6dd8-7d6f-5fcf-a744-1b12e2a14232","topicId":"329a162f-132a-4d7e-afd5-7ff2f86369d2","topicName":"Palliative care - nausea and vomiting","slug":"palliative-care-nausea-vomiting","lastRevised":"Last revised in October 2020","chapters":[{"id":"4cf6ed2e-fa29-54e9-8d93-4bd52407c5c4","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"2e3a3e75-af78-5547-a042-7aa68a341672","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"27d24f4a-dbc8-560f-b100-ca5287022d66","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"b433057a-92f0-5457-837c-f3f7235e44e6","slug":"changes","fullItemName":"Changes"},{"id":"540b41fe-3e71-5c29-9379-7493711a8a59","slug":"update","fullItemName":"Update"}]},{"id":"ed201382-7c29-58e9-ba5d-f5c415eb3bf3","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"7043600f-13dd-5980-b06d-73dab2266896","slug":"goals","fullItemName":"Goals"},{"id":"63b87fa3-3c3d-527b-9ac2-e856dd0c559e","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"6e3ee330-3c0d-5735-b8d5-76b606865d07","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"d1227949-2a90-5b29-abef-3895e05333c3","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"e2e036e5-217a-593d-947f-a8376f0f5e98","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"3885ba7b-9d6f-5262-a541-463284363660","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"b65bec71-2fa0-54e0-be57-13a917c2a697","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"a9561403-d5a9-5c9c-b6e6-c24410e9d9d3","slug":"definition","fullItemName":"Definition"},{"id":"d92b4aee-031c-58a4-b4b9-5d13767e0261","slug":"prevalence","fullItemName":"Prevalence"},{"id":"b1327253-7b93-5a44-b2f7-5e002ae90e8f","slug":"causes","fullItemName":"Causes"},{"id":"e321f36e-5ec2-5074-b128-109efef69a65","slug":"complications","fullItemName":"Complications"}]},{"id":"a4a81f08-7894-5ba4-a4e5-c5505f3e5250","fullItemName":"Management","slug":"management","subChapters":[{"id":"8691c12d-3ed6-5e16-bef3-667d198f6707","slug":"assessment","fullItemName":"Scenario: Assessment"},{"id":"e2566bf0-9d82-5bc7-9b5f-835384f56bc2","slug":"known-cause","fullItemName":"Scenario: Known cause"},{"id":"c8237819-4755-5cd8-ad7c-12735068c87a","slug":"unknown-cause","fullItemName":"Scenario: Unknown cause"},{"id":"145fe4aa-682c-5299-9906-a7bca2e98a9b","slug":"end-of-life","fullItemName":"Scenario: End of life"}]},{"id":"4d9745dc-8b36-500d-8e94-0e51611a4373","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"f61e929d-def9-58db-877e-a030bc91d3de","slug":"prescribing-an-anti-emetic","fullItemName":"Prescribing an anti-emetic"},{"id":"d39c4487-f9dc-5d1d-be98-95561ca991bd","slug":"prescribing-a-prokinetic","fullItemName":"Prescribing a prokinetic"},{"id":"23e74db2-9671-539b-8bcf-b5c4bdff23f9","slug":"prescribing-haloperidol","fullItemName":"Prescribing haloperidol"},{"id":"00a2a0a3-8bc1-5d27-a03f-6cd4624d1c38","slug":"prescribing-levomepromazine","fullItemName":"Prescribing levomepromazine"},{"id":"d0437d3a-566f-5df2-9800-1961ed4664e8","slug":"prescribing-cyclizine","fullItemName":"Prescribing cyclizine"},{"id":"e6d5c2a8-e2b8-55c5-afd4-46f2edcd4a30","slug":"prescribing-dexamethasone","fullItemName":"Prescribing dexamethasone"},{"id":"3042d096-a74b-5c66-8d18-8c233091e783","slug":"prescribing-hyoscine-butylbromide","fullItemName":"Prescribing hyoscine butylbromide"}]},{"id":"ba414d8a-38a1-5962-84ab-6051ffe6dfe9","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"26e42d0a-9ee9-50c5-9f2b-818da289f6e9","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"c0795c41-1865-5ab1-b820-e41b8b5d9aab","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"3076afc1-a703-524e-9ec9-995b34c4d386","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"08b8fc57-db22-518d-a528-777cb4e8d7dc","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"81928ac1-4f26-5da9-b11f-85d1cee4fbdd","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"5aee10d5-2771-547a-a52a-1fb430319da3","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"3cfa53b2-3d63-508d-80ea-c2a6293844fc","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"a4a81f08-7894-5ba4-a4e5-c5505f3e5250","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"ad5e4e96-cf1a-50ed-a5bf-ff894f9821cb","slug":"managing-known-cause","fullItemName":"Managing known cause","depth":3,"htmlHeader":"<!-- begin field d550663f-e3e8-4c0f-bc4e-0a544d93d97a --><h3>How should I manage nausea and vomiting of known cause?</h3><!-- end field d550663f-e3e8-4c0f-bc4e-0a544d93d97a -->","summary":null,"htmlStringContent":"<!-- begin item e7624e57-543e-461b-b5b8-4ef79aecaf41 --><!-- begin field 5aca3d1a-d44a-4b08-80d1-e117fb8a6f9e --><ul><li>Manage the underlying cause or correct reversible causes if possible and appropriate.</li><li>Try <a class=\"topic-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/management/known-cause/#simple-measures\">simple measures</a> to relieve symptoms.</li><li>Choose an anti-emetic according to the cause of nausea and vomiting such as:<ul><li><a class=\"topic-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/management/known-cause/#drug-induced-nausea-vomiting\">Drugs</a> (for example opioids, diuretics, nonsteroidal anti-inflammatory drugs, or antibiotics).</li><li><a class=\"topic-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/management/known-cause/#metabolic-causes-of-nausea-vomiting\">Metabolic causes</a> (for example hypercalcaemia, renal failure, or tumour toxins)</li><li><a class=\"topic-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/management/known-cause/#intracranial-disease-related-nausea-vomiting\">Intracranial disease</a> (for example raised intracranial pressure or brainstem/meningeal disease)</li><li><a class=\"topic-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/management/known-cause/#movement-related-nausea-vomiting\">Movement&nbsp;</a> (for example vestibular disease or tumour at the base of the skull)</li><li><a class=\"topic-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/management/known-cause/#bowel-obstruction-related-nausea-vomiting\">Bowel obstruction</a></li><li><a class=\"topic-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/management/known-cause/#nausea-vomiting-related-to-an-abdominal-or-pelvic-tumour\">Abdominal or pelvic tumour</a></li><li><a class=\"topic-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/management/known-cause/#gastric-stasis-related-nausea-vomiting\">Gastric stasis</a></li><li><a class=\"topic-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/management/known-cause/#anxiety-related-nausea-vomiting\">Anxiety</a></li></ul></li><li>Ascertain the most appropriate route of administration of the anti-emetic.</li><li>Prescribe anti-emetics regularly <em>and </em>as required.</li><li>Review the effectiveness of anti-emetic treatment every 24 hours.</li><li>Continue use of anti-emetics unless nausea and vomiting has resolved (for example the cause was self-limited or has been reversed).</li></ul><!-- end field 5aca3d1a-d44a-4b08-80d1-e117fb8a6f9e --><!-- end item e7624e57-543e-461b-b5b8-4ef79aecaf41 -->","subChapters":[{"id":"988a97d3-3386-5363-ab9c-d0587e83e3f6","slug":"antiemetics-receptor-affinity","fullItemName":"Antiemetics and receptor affinity","depth":4,"htmlHeader":"<!-- begin field 6a34a3a0-f91c-40fe-9660-7d5c4f5bcfc0 --><h4>Antiemetics and receptor affinity</h4><!-- end field 6a34a3a0-f91c-40fe-9660-7d5c4f5bcfc0 -->","summary":null,"htmlStringContent":"<!-- begin item 659598b8-7fba-40fc-a262-03dfc5dbf370 --><!-- begin field 660848f4-75cb-430d-8c80-b82b0275444b --><ul><li>Anti-emetics vary in their affinities for the receptors involved in the causes of nausea and vomiting (see Table 4).</li></ul><p><strong>Table 4</strong><strong>. </strong>Anti-emetics: receptor site affinities.</p><table><thead><tr><th colspan=\"1\"><p>Anti-emetic</p></th><th colspan=\"1\"><p>Dopamine D<sub>2</sub>antagonist</p></th><th colspan=\"1\"><p>Histamine H<sub>1</sub>antagonist</p></th><th colspan=\"1\"><p>Acetylcholine antagonist</p></th><th colspan=\"1\"><p>5-HT<sub>2</sub>antagonist</p></th></tr></thead><tbody><tr><td colspan=\"1\">Metoclopramide*</td><td colspan=\"1\">++</td><td colspan=\"1\">–</td><td colspan=\"1\">–</td><td colspan=\"1\">–</td></tr><tr><td colspan=\"1\">Domperidone†</td><td colspan=\"1\">++</td><td colspan=\"1\">–</td><td colspan=\"1\">–</td><td colspan=\"1\">–</td></tr><tr><td colspan=\"1\">Cyclizine</td><td colspan=\"1\">–</td><td colspan=\"1\">++</td><td colspan=\"1\">++</td><td colspan=\"1\">–</td></tr><tr><td colspan=\"1\">Hyoscine</td><td colspan=\"1\">–</td><td colspan=\"1\">–</td><td colspan=\"1\">+++</td><td colspan=\"1\">–</td></tr><tr><td colspan=\"1\">Haloperidol</td><td colspan=\"1\">+++</td><td colspan=\"1\">–</td><td colspan=\"1\">–</td><td colspan=\"1\">–</td></tr><tr><td colspan=\"1\">Levomepromazine</td><td colspan=\"1\">++</td><td colspan=\"1\">+++</td><td colspan=\"1\">++</td><td colspan=\"1\">+++</td></tr><tr><td colspan=\"5\">– none or insignificant; + slight; ++ moderate; +++ marked. * Metoclopramide in higher doses >= 100 mg, demonstrates 5-HT<sub>3</sub>-receptor antagonism. † Domperidone does not cross the blood brain barrier so the risk of extrapyramidal adverse effects (such as tremors, slurred speech, and dystonia) is negligible.</td></tr><tr><td colspan=\"5\"><strong>Information from</strong>: [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">Twycross, 2014</a>]</td></tr></tbody></table><!-- end field 660848f4-75cb-430d-8c80-b82b0275444b --><!-- end item 659598b8-7fba-40fc-a262-03dfc5dbf370 -->","subChapters":[]},{"id":"759b201b-f18a-5c45-9b70-90aec06940c6","slug":"basis-for-recommendation-48c","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field abd550c6-c02a-4ee0-84cd-bed6c13c34cb --><h4>Basis for recommendation</h4><!-- end field abd550c6-c02a-4ee0-84cd-bed6c13c34cb -->","summary":null,"htmlStringContent":"<!-- begin item 48c28168-90aa-4c59-8bcf-3a9d6d9d20a9 --><!-- begin field 57cac134-78b7-4dd1-9c8d-5fa86e24cf42 --><ul><li>Nausea and vomiting can be controlled in up to 70% of people in palliative care by using anti-emetics appropriate to the receptor site that is thought to contribute to the nausea and vomiting [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">Thompson, 2004</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">Mannix, 2006</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">Glare et al, 2011</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">Hamling, 2011</a>].</li></ul><!-- end field 57cac134-78b7-4dd1-9c8d-5fa86e24cf42 --><!-- end item 48c28168-90aa-4c59-8bcf-3a9d6d9d20a9 -->","subChapters":[]}]},{"id":"6160ae90-8c28-5880-ae0e-f1b7969c0eb5","slug":"simple-measures","fullItemName":"Simple measures","depth":3,"htmlHeader":"<!-- begin field c337ffb5-b658-4939-86a3-84a01d2ccaba --><h3>What simple measures may help nausea and vomiting in palliative care?</h3><!-- end field c337ffb5-b658-4939-86a3-84a01d2ccaba -->","summary":null,"htmlStringContent":"<!-- begin item f2d6805b-3f6c-4def-a7aa-f739b5266caa --><!-- begin field 40c0dcd1-9305-41fe-9df3-cc2669e59d5d --><ul><li>Make sure the person has access to a large bowl, tissues, and water.</li><li>The sight and smell of food or drink may provoke nausea:<ul><li>Provide a calm environment away from where food is usually prepared or consumed.</li><li>If the person is usually responsible for cooking, make alternative arrangements.</li><li>Make sure that meals are small and palatable — snacks consisting of a few mouthfuls are less challenging than big meals.</li><li>Carbohydrate meals are often better tolerated.</li><li>Offer cool, fizzy drinks (citrus flavours are often preferred) — these are more palatable than still or hot drinks.</li></ul></li><li>Consider parenteral hydration, if appropriate (in all people but those at the very end of life). Parenteral hydration, 500–1000 mL/24 hours, may help to reduce persistent nausea.</li><li>Consider the use of complementary therapies; relaxation and acupressure bands may be useful to relieve symptoms.</li><li>Consider cognitive behavioural therapy for anticipatory nausea or vomiting.</li><li>In general, avoid nasogastric suction. It has no role in the management of most causes of nausea and vomiting.</li></ul><!-- end field 40c0dcd1-9305-41fe-9df3-cc2669e59d5d --><!-- end item f2d6805b-3f6c-4def-a7aa-f739b5266caa -->","subChapters":[{"id":"a33e60f1-67f1-5120-9cb2-58d30786fb90","slug":"basis-for-recommendation-4a2","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field ac414665-aa61-442c-9056-becd6291cf18 --><h4>Basis for recommendation</h4><!-- end field ac414665-aa61-442c-9056-becd6291cf18 -->","summary":null,"htmlStringContent":"<!-- begin item 4a2b309d-b355-4b8a-b49e-261f67993e81 --><!-- begin field c6b8605a-e828-4167-9191-98c0f2208ab7 --><p>These recommendations are based on palliative care literature from textbooks [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">Twycross et al, 2009</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">Hardy, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">Regnard, 2010</a>] and published journal articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">Wright, 2005</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">Mannix, 2006</a>].</p><ul><li>CKS could not find studies relating to acupuncture or relaxation for people experiencing nausea and vomiting in general palliative care; the trials and reviews that were found related to chemotherapy-related nausea and vomiting (treatment of which is not covered in this CKS topic) and people experiencing nausea and vomiting who were not receiving palliative care (for example motion sickness, pregnancy, or post-operative nausea and vomiting):<ul><li>A review provides positive evidence that relaxation is effective for preventing nausea before, during, and after chemotherapy, and is usually a low-risk intervention [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">Ernst et al, 2006</a>]. In view of this, CKS extrapolated this evidence to recommend consideration of relaxation therapies for people receiving palliative care, since this may provide benefit with little chance of harm.</li><li>A paper written by a consultant in palliative care medicine suggests that although studies in the palliative care setting are lacking, case reports suggest that acupuncture can be helpful [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">Mannix, 2006</a>]. In the absence of stronger evidence relating to the general palliative care population, and considering the potential (albeit rare) adverse effects of acupuncture, CKS could not extrapolate this tentatively positive evidence on acupuncture for chemotherapy-induced nausea [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">Ernst et al, 2006</a>] to make a recommendation.</li></ul></li><li>Expert opinion in a textbook suggests that nasogastric suction has no role in the management of most causes of nausea and vomiting but may be useful in [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">Regnard, 2010</a>]:<ul><li>Gastric outflow or duodenal obstruction — to reduce high volume of vomiting.</li><li>Gastric atony ('floppy stomach') — a nasogastric tube can be passed easily and removed after all the fluid and air has been aspirated.</li><li>Faecal vomiting.</li></ul></li></ul><!-- end field c6b8605a-e828-4167-9191-98c0f2208ab7 --><!-- end item 4a2b309d-b355-4b8a-b49e-261f67993e81 -->","subChapters":[]}]},{"id":"bccbb5f2-cde8-5271-be69-7bc69aff97a8","slug":"drug-induced-nausea-vomiting","fullItemName":"Drug-induced nausea and vomiting","depth":3,"htmlHeader":"<!-- begin field e19c5e4d-1ba9-4540-8d2c-95e346f2aad6 --><h3>How should I treat drug-induced nausea and vomiting?</h3><!-- end field e19c5e4d-1ba9-4540-8d2c-95e346f2aad6 -->","summary":null,"htmlStringContent":"<!-- begin item 7cd0c35a-405b-4bfd-a5c9-f8ad32c326fe --><!-- begin field 08a23cf1-9245-4a23-93c6-7a053d4aed80 --><ul><li><strong>Review current medication use:</strong><ul><li>Discontinue use of any unnecessary medications.</li><li>Check blood levels if appropriate (for example with digoxin, phenytoin, and carbamazepine).</li></ul></li><li><strong>For chemotherapy-induced nausea and vomiting: </strong>seek advice from the specialist who is supervising the person's chemotherapy.</li><li><strong>For chemically induced nausea and vomiting (most drugs, including opioids): </strong>give haloperidol via the most appropriate route of administration.<ul><li>Usual oral dose: 1.5 mg at night or twice daily, titrate up to a maximum dose of 10 mg daily (some experts suggest a lower starting dose of 0.5 mg).</li><li>As-required dose: oral, 1.5mg; subcutaneous injection, 1.25–2.5 mg.</li><li>Syringe driver dose per 24 hours: 2.5–10 mg.</li></ul></li><li><strong>To manage </strong><strong>gastrointestinal irritation (for example due to nonsteroidal anti-inflammatory drugs, some antibiotics, or iron supplements): </strong>change the drug if possible, or consider gastroprotection.</li><li><strong>To manage nausea and vomiting caused by </strong><strong>antimuscarinic drugs (for example amitriptyline, lofepramine, or opioids): </strong>treat as for <a class=\"topic-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/management/known-cause/#gastric-stasis-related-nausea-vomiting\">gastric stasis</a>.</li></ul><!-- end field 08a23cf1-9245-4a23-93c6-7a053d4aed80 --><!-- end item 7cd0c35a-405b-4bfd-a5c9-f8ad32c326fe -->","subChapters":[{"id":"b20043b9-7fd6-5692-9e08-0a37adc36258","slug":"basis-for-recommendation-ff4","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field c67d252b-c650-4484-9b53-0a333e8a7182 --><h4>Basis for recommendation</h4><!-- end field c67d252b-c650-4484-9b53-0a333e8a7182 -->","summary":null,"htmlStringContent":"<!-- begin item ff4f9ab2-39fd-4857-8ba1-7e07c6f6e3d3 --><!-- begin field 428c4afb-61de-4100-82df-1e0cbefd319d --><p>These recommendations are consistent with specialist palliative care guidelines for the management of nausea and vomiting [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">NHS Scotland, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">Lothian Palliative Care Guidelines Group, 2010</a>] and on palliative care literature from textbooks [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">Regnard, 2010</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">Twycross, 2014</a>].</p><ul><li>The prevention and management of nausea and vomiting due to cytotoxic drugs is primarily the responsibility of the specialist prescribing those drugs [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">NHS Scotland, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">Lothian Palliative Care Guidelines Group, 2010</a>].</li><li>Drugs such as opioids, cytotoxics, and some antibiotics cause nausea and vomiting by stimulating dopamine type 2 (D<sub>2</sub>) receptors in the chemoreceptor trigger zone (CTZ) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">Hardy, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">Twycross, 2014</a>]. Haloperidol is the anti-emetic of choice because it is the most potent antagonist of D<sub>2</sub>receptors in the CTZ [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">Lothian Palliative Care Guidelines Group, 2010</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">Hardy, 2015</a>].<ul><li>Haloperidol is a centrally acting anti-emetic, useful for nausea and vomiting induced by drugs, toxins, and metabolites [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">Northern England Clinical Networks, 2016</a>].</li></ul></li><li>The recommended anti-emetic doses are consistent with specialist palliative care guidelines for the management of nausea and vomiting [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">NHS Scotland, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">Lothian Palliative Care Guidelines Group, 2010</a>], palliative care literature from a textbook [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">Twycross, 2014</a>], and the British National Formulary [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">BNF 72, 2016</a>].<ul><li>Expert opinion from specialist palliative care guidelines [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">Lothian Palliative Care Guidelines Group, 2010</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">Northern England Clinical Networks, 2016</a>] and from CKS expert reviewers is that a lower starting dose of haloperidol (that is 0.5 mg instead of 1.5 mg) should be used for managing nausea and vomiting in a palliative care situation.</li></ul></li></ul><!-- end field 428c4afb-61de-4100-82df-1e0cbefd319d --><!-- end item ff4f9ab2-39fd-4857-8ba1-7e07c6f6e3d3 -->","subChapters":[]}]},{"id":"9028d257-792b-575c-a52b-3af5c665277e","slug":"metabolic-causes-of-nausea-vomiting","fullItemName":"Metabolic causes of nausea and vomiting","depth":3,"htmlHeader":"<!-- begin field f0a5bb21-fd64-44ae-825a-e2d5077d2cf9 --><h3>How should I treat nausea and vomiting due to metabolic causes?</h3><!-- end field f0a5bb21-fd64-44ae-825a-e2d5077d2cf9 -->","summary":null,"htmlStringContent":"<!-- begin item 427e927f-13e9-4e20-a9b5-52586a5098b2 --><!-- begin field 18c83398-3d7b-46bb-8d00-4c13c555a44f --><ul><li><strong>If hypercalcaemia is present </strong>(corrected serum calcium concentration greater than 2.8 mmol/L), arrange hospital admission, if appropriate.<ul><li>Management of hypercalcaemia usually involves admission for intravenous rehydration and bisphosphonates.</li><li>Correction of hypercalcaemia may not always be appropriate in people near the end of life.</li><li>For more information, see the <a class=\"topic-reference external-reference\" href=\"/topics/hypercalcaemia/management/known-malignancy/\">Scenario: Known cancer</a> in the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/hypercalcaemia/\">Hypercalcaemia</a>.</li></ul></li><li><strong>To manage metabolic causes of nausea and vomiting: </strong>give haloperidol via the most appropriate route of administration.<ul><li>Usual oral dose: 1.5 mg at night or twice daily, titrate up to a maximum dose of 10 mg daily (some experts suggest a lower starting dose of 0.5 mg).</li><li>As-required dose: oral, 1.5mg; subcutaneous injection, 1.25–2.5 mg.</li><li>Syringe driver dose per 24 hours: 2.5–10 mg.</li></ul></li></ul><!-- end field 18c83398-3d7b-46bb-8d00-4c13c555a44f --><!-- end item 427e927f-13e9-4e20-a9b5-52586a5098b2 -->","subChapters":[{"id":"b32c2b15-e857-5a05-8849-a6d56cb7dadd","slug":"basis-for-recommendation-78f","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 2ce6317d-b1a6-4969-a0cd-75f304806444 --><h4>Basis for recommendation</h4><!-- end field 2ce6317d-b1a6-4969-a0cd-75f304806444 -->","summary":null,"htmlStringContent":"<!-- begin item 78f7f62d-b118-4f9c-8d86-eb2580aeeb15 --><!-- begin field 3c06909f-7934-4eb9-8d51-92602c922f67 --><p>These recommendations are consistent with specialist palliative care guidelines for the management of nausea and vomiting [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">NHS Scotland, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">Lothian Palliative Care Guidelines Group, 2010</a>] and on palliative care literature from textbooks [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">Regnard, 2010</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">Twycross, 2014</a>].</p><ul><li>Metabolic causes of nausea and vomiting, for example organ failure and hypercalcaemia, cause nausea and vomiting by stimulating dopamine type 2 (D<sub>2</sub>) receptors on the chemoreceptor trigger zone (CTZ) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">Hardy, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">Twycross, 2014</a>]. Nausea can be controlled by using a central dopamine antagonist such as haloperidol [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">Hardy, 2015</a>].</li><li>Haloperidol is the most potent antagonist of D<sub>2</sub>receptors on the CTZ [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">Hardy, 2015</a>] and is useful for relieving nausea and vomiting associated with stimulation of the D<sub>2</sub>receptors on the CTZ [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">Lothian Palliative Care Guidelines Group, 2010</a>].</li><li>Haloperidol is a centrally acting anti-emetic useful for nausea and vomiting induced by drugs, toxins, and metabolites [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">Northern England Clinical Networks, 2016</a>].</li><li>The recommended anti-emetic doses are consistent with specialist palliative care guidelines for the management of nausea and vomiting [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">NHS Scotland, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">Lothian Palliative Care Guidelines Group, 2010</a>], palliative care literature from a textbook [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">Twycross, 2014</a>], and the British National Formulary [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">BNF 72, 2016</a>].<ul><li>Expert opinion from specialist palliative care guidelines [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">Lothian Palliative Care Guidelines Group, 2010</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">Northern England Clinical Networks, 2016</a>] and from expert reviewers of this CKS topic is that a lower starting dose of haloperidol (that is 0.5 mg instead of 1.5 mg) should be used for managing nausea and vomiting in a palliative care situation.</li></ul></li></ul><!-- end field 3c06909f-7934-4eb9-8d51-92602c922f67 --><!-- end item 78f7f62d-b118-4f9c-8d86-eb2580aeeb15 -->","subChapters":[]}]},{"id":"70e75cab-5f25-5269-b09a-1db40fd1e822","slug":"intracranial-disease-related-nausea-vomiting","fullItemName":"Intracranial disease-related nausea and vomiting","depth":3,"htmlHeader":"<!-- begin field 4e882e12-eff5-4bf7-aec4-1c523f2cde20 --><h3>How should I treat nausea and vomiting due to intracranial disease?</h3><!-- end field 4e882e12-eff5-4bf7-aec4-1c523f2cde20 -->","summary":null,"htmlStringContent":"<!-- begin item 27c0add4-068c-472d-a076-4f74b6e8cf29 --><!-- begin field dcc2ac06-8c8c-4cdc-ad81-99a7bcdcf905 --><ul><li><strong>For nausea and vomiting due to intracranial disease: </strong>give cyclizine via the most appropriate route of administration.<ul><li>Usual oral dose: 25–50 mg every 8 hours up to a maximum dose of 150 mg daily.</li><li>Immediate/as-required dose: oral and subcutaneous injection, 25–50 mg every 8 hours.</li><li>Syringe driver dose per 24 hours: 50–150 mg.</li></ul></li><li><strong>If intracranial pressure is raised:</strong><ul><li>Consider referral for radiotherapy for all people with raised intracranial pressure due to a tumour.</li><li>Consider adding high-dose dexamethasone to cyclizine:<ul><li>A suitable dose might be 8–16 mg daily for up to 7 days. If dexamethasone has been given for longer than 5 days, or there is a risk of recurrent severe symptoms, or repeated courses of dexamethasone have been given, dexamethasone should be reduced by 2 mg daily every 5–7 days.</li><li>Stop dexamethasone therapy if there is no obvious benefit within 3–7 days, or if it becomes ineffective.</li></ul></li></ul></li></ul><!-- end field dcc2ac06-8c8c-4cdc-ad81-99a7bcdcf905 --><!-- end item 27c0add4-068c-472d-a076-4f74b6e8cf29 -->","subChapters":[{"id":"0124f173-b9fb-5a84-b6fb-62ca0f8f0f20","slug":"basis-for-recommendation-4f5","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 0429d0b3-ee34-4beb-a603-5e50056f6f7d --><h4>Basis for recommendation</h4><!-- end field 0429d0b3-ee34-4beb-a603-5e50056f6f7d -->","summary":null,"htmlStringContent":"<!-- begin item 4f55d155-2e37-4fc8-b365-191713f7449a --><!-- begin field 7a1fdcbf-7d5e-4baa-9238-823bf2e0318d --><p>These recommendations are consistent with specialist palliative care guidelines for the management of nausea and vomiting [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">NHS Scotland, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">Lothian Palliative Care Guidelines Group, 2010</a>] and on palliative care literature from textbooks [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">Regnard, 2010</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">Twycross, 2014</a>].</p><ul><li>In intracranial disease, meningeal mechanoreceptors stimulate the histamine type 1 (H<sub>1</sub>) receptors in the vomiting centre [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">Hardy, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">Twycross, 2014</a>].</li><li>Cyclizine is an antihistaminic, anticholinergic anti-emetic [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">Northern England Clinical Networks, 2016</a>] which acts principally on H<sub>1</sub>receptors in the vomiting centre [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">Lothian Palliative Care Guidelines Group, 2010</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">Hardy, 2015</a>]; [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">Twycross, 2014</a>].<ul><li>Cyclizine is useful for managing nausea and vomiting caused by raised intracranial pressure [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">BNF 72, 2016</a>].</li></ul></li><li>The recommended anti-emetic doses are consistent with specialist palliative care guidelines for the management of nausea and vomiting [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">NHS Scotland, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">Lothian Palliative Care Guidelines Group, 2010</a>], palliative care literature from a textbook [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">Twycross, 2014</a>], and the British National Formulary [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">BNF 72, 2016</a>].</li><li>The recommendation to add dexamethasone to cyclizine for raised intracranial pressure is consistent with specialist palliative care guidelines for the management of nausea and vomiting [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">NHS Scotland, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">Lothian Palliative Care Guidelines Group, 2010</a>] and on palliative care literature from textbooks [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">Regnard, 2010</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">Twycross, 2014</a>].<ul><li>The recommended dose, duration of treatment, and dose adjustment of dexamethasone are based on specialist palliative care guidelines for the management of nausea and vomiting [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">NHS Scotland, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">Northern England Clinical Networks, 2016</a>].</li></ul></li></ul><!-- end field 7a1fdcbf-7d5e-4baa-9238-823bf2e0318d --><!-- end item 4f55d155-2e37-4fc8-b365-191713f7449a -->","subChapters":[]}]},{"id":"82a04eb9-b67a-50dd-8672-f2e7d3055d2f","slug":"movement-related-nausea-vomiting","fullItemName":"Movement-related nausea and vomiting","depth":3,"htmlHeader":"<!-- begin field 33b8c59a-688b-4ee4-aedc-f85e2bd465de --><h3>How should I treat movement-related nausea and vomiting?</h3><!-- end field 33b8c59a-688b-4ee4-aedc-f85e2bd465de -->","summary":null,"htmlStringContent":"<!-- begin item 105af2ec-79de-49c5-9238-5608192b0aad --><!-- begin field a4ce8d85-eb92-4824-9ff2-1159387364ac --><ul><li><strong>For vestibular disturbance (for example diseases of the inner ear and motion sickness): </strong>give cyclizine via the most appropriate route of administration.<ul><li>Usual oral dose: 25–50 mg every 8 hours up to a maximum dose of 150 mg daily.</li><li>As-required dose: oral and subcutaneous injection, 25–50 mg every 8 hours.</li><li>Syringe driver dose/24 hours: 50–150 mg.</li></ul></li><li>Be aware that movement may intensify symptoms of abdominal and pelvic tumour. For more details see <a class=\"topic-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/management/known-cause/#nausea-vomiting-related-to-an-abdominal-or-pelvic-tumour\">Nausea and vomiting related to an abdominal or pelvic tumour</a>.</li></ul><!-- end field a4ce8d85-eb92-4824-9ff2-1159387364ac --><!-- end item 105af2ec-79de-49c5-9238-5608192b0aad -->","subChapters":[{"id":"9b0fa29b-1689-50ea-95bc-a5f36797092d","slug":"basis-for-recommendation-fe4","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field a463ff46-de16-454d-9616-e315576367fd --><h4>Basis for recommendation</h4><!-- end field a463ff46-de16-454d-9616-e315576367fd -->","summary":null,"htmlStringContent":"<!-- begin item fe41ff67-20d5-4301-932b-e55ade5d913b --><!-- begin field 4448649d-8d34-44fe-8037-08c243384172 --><p>These recommendations are consistent with specialist palliative care guidelines for the management of nausea and vomiting [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">NHS Scotland, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">Lothian Palliative Care Guidelines Group, 2010</a>] and on palliative care literature from textbooks [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">Regnard, 2010</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">Twycross, 2014</a>].</p><ul><li>Movement-associated nausea and vomiting may be caused by opioids, gut distortion, or gastroparesis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">Hardy, 2015</a>].</li><li>Cyclizine is an antihistaminic, anticholinergic anti-emetic [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">Northern England Clinical Networks, 2016</a>]. It acts principally on histamine (H<sub>1</sub>) receptors in the vomiting centre; however, it also acts on H<sub>1</sub>receptors on vestibular afferents [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">Lothian Palliative Care Guidelines Group, 2010</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">Hardy, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">Twycross, 2014</a>].<ul><li>Cyclizine is useful for managing nausea and vomiting caused by motion sickness [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">BNF 72, 2016</a>].</li></ul></li><li>The recommended anti-emetic doses are consistent with specialist palliative care guidelines for the management of nausea and vomiting [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">NHS Scotland, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">Lothian Palliative Care Guidelines Group, 2010</a>], palliative care literature from a textbook [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">Twycross, 2014</a>], and the British National Formulary [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">BNF 72, 2016</a>].</li></ul><!-- end field 4448649d-8d34-44fe-8037-08c243384172 --><!-- end item fe41ff67-20d5-4301-932b-e55ade5d913b -->","subChapters":[]}]},{"id":"304cd3e6-28e8-518b-b10a-4c3f69d770ef","slug":"bowel-obstruction-related-nausea-vomiting","fullItemName":"Bowel obstruction-related nausea and vomiting","depth":3,"htmlHeader":"<!-- begin field 064f50a0-1f12-426e-83fd-c8b2dbd7eb7b --><h3>How should I treat nausea and vomiting due to bowel obstruction?</h3><!-- end field 064f50a0-1f12-426e-83fd-c8b2dbd7eb7b -->","summary":null,"htmlStringContent":"<!-- begin item df2e48f9-5b7f-41d1-86c4-80cfca41f0fa --><!-- begin field 6668538d-d6ae-4a07-a1de-d6400e6782e4 --><ul><li>Bowel obstruction may be due to peristaltic failure or mechanical obstruction. When managing nausea and vomiting due to bowel obstruction:<ul><li>If necessary, seek specialist advice early as management can be complex.</li><li>A syringe driver may be needed because the oral route is often unreliable.</li></ul></li><li><strong>To manage bowel obstruction due to peristaltic failure:</strong><ul><li>If possible, stop drugs which decrease peristalsis (for example cyclizine, tricyclic antidepressants, or opioids).</li><li>If there is no colic: start a prokinetic anti-emetic (for example metoclopramide, 30–100 mg/24 hours) via continuous subcutaneous infusion (CSCI).</li><li>If colic develops: stop the prokinetic anti-emetic and treat as for mechanical obstruction.</li></ul></li><li><strong>To manage bowel obstruction due to mechanical obstruction:</strong><ul><li>Exclude constipation, or treat if present:<ul><li>To relieve and prevent constipation, docusate or Movicol<sup>® </sup>should be titrated to produce a comfortable stool without colic. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/palliative-care-constipation/\">Palliative care - constipation</a>.</li></ul></li><li>Treat nausea with cyclizine, 50–150 mg/24 hours via CSCI:<ul><li>If nausea persists, add haloperidol, 2.5–10 mg/24 hours or as a single night-time dose, or levomepromazine, 5–25 mg/24 hours or as a single night-time dose.</li><li>Avoid prokinetics.</li></ul></li><li>Treat colic with an antimuscarinic drug (for example hyoscine butylbromide, 20 mg immediately by subcutaneous injection, then 60–100 mg/24 hours via CSCI).</li><li>Manage large-volume vomiting with an antisecretory drug (for example hyoscine butylbromide or octreotide).<ul><li>Hyoscine will reduce secretions and treat colic, but its full antisecretory effect is achieved after about 3 days.</li><li>If large volume vomiting persists, consider using octreotide if a more rapid or profound antisecretory effect is required. This may require admission, depending on the experience of the primary healthcare professional and the availability of octreotide in the community.</li></ul></li></ul></li></ul><!-- end field 6668538d-d6ae-4a07-a1de-d6400e6782e4 --><!-- end item df2e48f9-5b7f-41d1-86c4-80cfca41f0fa -->","subChapters":[{"id":"ef073c64-5d82-5672-bc31-b630a557503f","slug":"basis-for-recommendation-5e7","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 057925e9-2224-4ef4-a934-06379cbdb90e --><h4>Basis for recommendation</h4><!-- end field 057925e9-2224-4ef4-a934-06379cbdb90e -->","summary":null,"htmlStringContent":"<!-- begin item 5e73659e-2456-4ba7-9af6-4dca1a5ebf34 --><!-- begin field 1890512c-fc35-4ab6-8251-87b93e714d3c --><p>These recommendations are consistent with specialist palliative care guidelines for the management of nausea and vomiting [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">NHS Scotland, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">Lothian Palliative Care Guidelines Group, 2010</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">Northern England Clinical Networks, 2016</a>] and on palliative care literature from textbooks [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">Regnard, 2010</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">Twycross, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">Hardy, 2015</a>].</p><ul><li><strong>Peristaltic failure</strong><ul><li>Bowel obstruction due to peristaltic failure may be due to autonomic neuropathy or a wide spread intra-abdominal cancer [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">Lothian Palliative Care Guidelines Group, 2010</a>]. Mechanoreceptors in the gut stimulate the vagus nerve which acts on the vomiting centre [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">Hardy, 2015</a>].</li><li>Peristaltic failure is characterized by partial obstruction, reduced bowel sounds, and the absence of colic [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">Lothian Palliative Care Guidelines Group, 2010</a>].</li><li>Prokinetic anti-emetics (such as metoclopramide) are useful for managing nausea and vomiting due to peristaltic failure because they act predominantly in the gut to antagonize dopamine type 2 (D<sub>2</sub>) receptors. Prokinetics also stimulate serotonin type 4 (5HT<sub>4</sub>) receptors in the gut, and the subsequent release of acetylcholine appears to play an important role in restoring normal peristalsis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">Hardy, 2015</a>]. Cyclizine is not recommended because its anticholinergic properties will further decrease peristalsis.</li></ul></li><li><strong>Bowel obstruction</strong><ul><li>Cyclizine is useful for managing vagally-mediated nausea and vomiting caused by mechanical bowel obstruction [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">BNF 72, 2016</a>]. Haloperidol is useful with cyclizine in bowel obstruction if nausea persists with cyclizine alone [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">Northern England Clinical Networks, 2016</a>].</li><li>Levomepromazine is a broad-spectrum anti-emetic useful for mechanical obstruction, and for persistent nausea and vomiting uncontrolled by other anti-emetics. It should be give at night because of the risk of sedation and hypotension (even at low dose) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">Twycross et al, 2009</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">Northern England Clinical Networks, 2016</a>].</li><li>Prokinetic anti-emetics should be avoided in people with bowel obstruction as they may induce colic [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">Hardy, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">Northern England Clinical Networks, 2016</a>].</li><li>Hyoscine butylbromide is used for managing bowel colic (it reduces gastrointestinal motility) and excessive gastrointestinal secretions (it reduces the volume of vomit in obstruction) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">BNF 72, 2016</a>].</li><li>Octreotide, a somatostatin analogue, is a useful adjunct in managing complete mechanical bowel obstruction. It stimulates water and electrolyte absorption and inhibits water secretion in the small bowel [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">BNF 72, 2016</a>]. It is fast acting; however, its cost limits its use.</li></ul></li><li>The recommended doses of anti-emetics are consistent with the British National Formulary [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">BNF 72, 2016</a>] and the Palliative Care Formulary [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">Twycross, 2014</a>].</li></ul><!-- end field 1890512c-fc35-4ab6-8251-87b93e714d3c --><!-- end item 5e73659e-2456-4ba7-9af6-4dca1a5ebf34 -->","subChapters":[]}]},{"id":"3e6417c1-be15-5439-be8a-600c5dea0585","slug":"nausea-vomiting-related-to-an-abdominal-or-pelvic-tumour","fullItemName":"Nausea and vomiting related to an abdominal or pelvic tumour","depth":3,"htmlHeader":"<!-- begin field c540664d-e3d6-4a64-b671-9c271550b6b1 --><h3>How should I treat nausea and vomiting due to an abdominal or pelvic tumour?</h3><!-- end field c540664d-e3d6-4a64-b671-9c271550b6b1 -->","summary":null,"htmlStringContent":"<!-- begin item 5f43346d-e9ae-4b4d-aa8d-7b7dd6281f6a --><!-- begin field a19c667a-3b47-426e-b9ba-cce2527682a7 --><ul><li><strong>To manage </strong><strong>nausea and vomiting due to distension, compression, or disturbance of abdominal or pelvic organs (for example bowel or liver): </strong>give cyclizine via the most appropriate route of administration.<ul><li>Usual oral dose: 25–50 mg every 8 hours up to a maximum dose of 150 mg daily.</li><li>As-required dose: oral and subcutaneous injection, 25–50 mg every 8 hours.</li><li>Syringe driver dose per 24 hours: 50–150 mg.</li></ul></li><li><strong>If bowel obstruction is suspected: </strong>see <a class=\"topic-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/management/known-cause/#bowel-obstruction-related-nausea-vomiting\">Bowel obstruction-related nausea and vomiting</a>.</li></ul><!-- end field a19c667a-3b47-426e-b9ba-cce2527682a7 --><!-- end item 5f43346d-e9ae-4b4d-aa8d-7b7dd6281f6a -->","subChapters":[{"id":"c13d86ce-a8a3-5037-9640-e5676b39c0ee","slug":"basis-for-recommendation-1fa","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field f3ca256d-4f4d-4ae8-82fc-9ce959d3a343 --><h4>Basis for recommendation</h4><!-- end field f3ca256d-4f4d-4ae8-82fc-9ce959d3a343 -->","summary":null,"htmlStringContent":"<!-- begin item 1fab274d-80d0-4bc3-a356-1d32d159cefc --><!-- begin field 1db3a918-f182-4257-8540-264ffabea7d1 --><p>These recommendations are consistent with specialist palliative care guidelines for the management of nausea and vomiting [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">NHS Scotland, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">Lothian Palliative Care Guidelines Group, 2010</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">Northern England Clinical Networks, 2016</a>] and on palliative care literature from textbooks [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">Regnard, 2010</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">Twycross, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">Hardy, 2015</a>].</p><ul><li>Vomiting commonly occurs in advanced intra-abdominal, retroperitoneal or pelvic malignancy because mechanoreceptors in the bowel wall or capsules of organs are stimulated by stretch or distortion by a tumour, stimulating the vomiting centre via the vagus and splanchnic nerves [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">Hardy, 2015</a>].</li><li>Anti-emetics active at the vomiting centre may therefore help to palliate nausea in this situation [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">Hardy, 2015</a>]; cyclizine acts on acetylcholine and histamine type 1 (H<sub>1</sub>) receptors in the vomiting centre [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">Mannix, 2006</a>]; [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">Twycross, 2014</a>].</li><li>The recommended anti-emetic doses are consistent with specialist palliative care guidelines for the management of nausea and vomiting [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">NHS Scotland, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">Lothian Palliative Care Guidelines Group, 2010</a>], palliative care literature from a textbook [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">Twycross, 2014</a>], and the British National Formulary [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">BNF 72, 2016</a>].</li></ul><!-- end field 1db3a918-f182-4257-8540-264ffabea7d1 --><!-- end item 1fab274d-80d0-4bc3-a356-1d32d159cefc -->","subChapters":[]}]},{"id":"fdffde89-8e43-5426-8d0c-bbea21b87519","slug":"gastric-stasis-related-nausea-vomiting","fullItemName":"Gastric stasis-related nausea and vomiting","depth":3,"htmlHeader":"<!-- begin field 2aeb9406-b739-47f2-93c2-ff7f174a32bd --><h3>How should I treat nausea and vomiting due to gastric stasis?</h3><!-- end field 2aeb9406-b739-47f2-93c2-ff7f174a32bd -->","summary":null,"htmlStringContent":"<!-- begin item ba689df1-710f-4177-9954-866861683c7f --><!-- begin field 906be231-a5de-4545-b2b6-d0b063a9ebbb --><ul><li><strong>For manage nausea and vomiting due to gastric stasis: </strong>give metoclopramide.<ul><li>Unless gastric stasis is mild, start metoclopramide parenterally (10–20 mg every 8 hours by subcutaneous injection or 30–100 mg/24 hours via continuous subcutaneous infusion).</li><li>If extrapyramidal effects are a problem with metoclopramide, use domperidone (30–60 mg rectally every 4–8 hours).</li></ul></li><li><strong>Do not give prokinetics concurrently with drugs with antimuscarinic activity </strong>(for example cyclizine and hyoscine).</li></ul><!-- end field 906be231-a5de-4545-b2b6-d0b063a9ebbb --><!-- end item ba689df1-710f-4177-9954-866861683c7f -->","subChapters":[{"id":"ce213ffd-625f-516d-b0ff-a1237cac81ef","slug":"basis-for-recommendation-55e","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 2c235660-ac83-44a1-810d-a9697987a088 --><h4>Basis for recommendation</h4><!-- end field 2c235660-ac83-44a1-810d-a9697987a088 -->","summary":null,"htmlStringContent":"<!-- begin item 55e1225f-9b3b-4feb-81ad-c9947fde0595 --><!-- begin field 7bde505b-391f-4248-83c6-4805f4813aac --><p>These recommendations are consistent with specialist palliative care guidelines for the management of nausea and vomiting [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">NHS Scotland, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">Lothian Palliative Care Guidelines Group, 2010</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">Northern England Clinical Networks, 2016</a>] and on palliative care literature from textbooks [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">Regnard, 2010</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">Twycross, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">Hardy, 2015</a>].</p><ul><li>In gastric stasis, gastric receptors stimulate the vagus nerve which acts on the vomiting centre. Prokinetic anti-emetics (such as metoclopramide) are useful for managing nausea and vomiting due to gastric stasis because they act predominantly in the gut to antagonize dopamine type 2 (D<sub>2</sub>) receptors [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">Hardy, 2015</a>].<ul><li>Unlike metoclopramide, domperidone does not cross the blood brain barrier so the risk of extra-pyramidal adverse effects are less [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">Hardy, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">BNF 72, 2016</a>].</li></ul></li><li>CKS are aware that the European Medicines Agency (EMA) has issued advice restricting the use of metoclopramide and domperidone [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">EMA, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">European Medicines Agency, 2014</a>]. Following clarification from the EMA this advice does not apply to to unlicensed uses of metoclopramide (for example palliative care) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">BNF 72, 2016</a>].</li><li>Prokinetics should not be used concurrently with drugs with antimuscarinic activity (for example cyclizine and hyoscine) because antimuscarinic drugs competitively block the action of prokinetics [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">Lothian Palliative Care Guidelines Group, 2010</a>]; [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">Twycross, 2014</a>].</li><li>The recommended anti-emetic doses are consistent with specialist palliative care guidelines for the management of nausea and vomiting [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">NHS Scotland, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">Lothian Palliative Care Guidelines Group, 2010</a>], palliative care literature from a textbook [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">Twycross, 2014</a>], and the British National Formulary [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">BNF 72, 2016</a>].</li></ul><!-- end field 7bde505b-391f-4248-83c6-4805f4813aac --><!-- end item 55e1225f-9b3b-4feb-81ad-c9947fde0595 -->","subChapters":[]}]},{"id":"8f0abc5b-dd90-57af-b282-a921413185e1","slug":"anxiety-related-nausea-vomiting","fullItemName":"Anxiety-related nausea and vomiting","depth":3,"htmlHeader":"<!-- begin field 1faf6369-9fab-4643-9bd3-982b86b294d6 --><h3>How should I treat anxiety-related nausea and vomiting?</h3><!-- end field 1faf6369-9fab-4643-9bd3-982b86b294d6 -->","summary":null,"htmlStringContent":"<!-- begin item 45d081f3-8fbe-47ea-b7ab-953d12cbe62c --><!-- begin field 7e5d8b16-1446-47d9-8c8c-7a1199261656 --><ul><li>Manage anxiety independently, according to the person's prognosis.</li><li>Consider a benzodiazepine (for example lorazepam, 0.5–1 mg sublingually) or levomepromazine (3–6 mg orally or 2.5–6.25 mg by subcutaneous injection).</li></ul><!-- end field 7e5d8b16-1446-47d9-8c8c-7a1199261656 --><!-- end item 45d081f3-8fbe-47ea-b7ab-953d12cbe62c -->","subChapters":[{"id":"ff3a1c46-71e9-59cf-865f-0c691b6ff19c","slug":"basis-for-recommendation-5b6","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field a9b4246f-868c-40db-8769-8caab8b9ea41 --><h4>Basis for recommendation</h4><!-- end field a9b4246f-868c-40db-8769-8caab8b9ea41 -->","summary":null,"htmlStringContent":"<!-- begin item 5b64fe4f-4b75-4f57-b865-b35de8acbf7a --><!-- begin field aef833b7-4b16-4a81-9a53-91710e822d15 --><p>These recommendations are based on UK specialist palliative care guidelines on the management of nausea and vomiting [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">Northern England Clinical Networks, 2016</a>] and on palliative care literature from textbooks [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">Hardy, 2015</a>]</p><ul><li>Expert opinion is divided as to whether diazepam should be used in this situation. Whilst some experts recommend diazepam because it has a long half-life, thus preventing as required use of anxiolytics [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">Breitbart et al, 2010</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">Hardy, 2015</a>], others advise that diazepam is avoided to prevent toxic accumulation due to impaired metabolism in debilitated people [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">Breitbart et al, 2010</a>]. In addition, concurrent administration of diazepam with other sedative drugs (including strong opioids) may lead to excessive sedation.</li></ul><!-- end field aef833b7-4b16-4a81-9a53-91710e822d15 --><!-- end item 5b64fe4f-4b75-4f57-b865-b35de8acbf7a -->","subChapters":[]}]},{"id":"ad49371b-66f5-57ac-8967-2d6b47e76840","slug":"action-if-first-line-anti-emetic-fails","fullItemName":"Action if first-line anti-emetic fails","depth":3,"htmlHeader":"<!-- begin field 0b5e86ef-3a63-46b0-b578-1f04b4287e43 --><h3>What should I do if a first-line anti-emetic has not worked?</h3><!-- end field 0b5e86ef-3a63-46b0-b578-1f04b4287e43 -->","summary":null,"htmlStringContent":"<!-- begin item 4d9090a3-bf11-48b5-98ef-b1bd5aaa6d18 --><!-- begin field 92e74ea3-406b-4513-9736-349baccdcefd --><ul><li>If a single first-line anti-emetic does not relieve nausea and vomiting:<ul><li>Confirm that the cause of nausea and vomiting has been correctly identified.</li><li>Optimize the dose of the first-line anti-emetic.</li><li>Consider the need for an alternative route of administration.</li></ul></li><li>If nausea and vomiting persist after two or three doses of optimal first-line anti-emetic:<ul><li>Change to an anti-emetic with a different action,<em>or</em>combine anti-emetics with complementary action.<ul><li>Do not combine prokinetics (metoclopramide or domperidone) with antimuscarinics (for example hyoscine, cyclizine, or levomepromazine).</li><li>About one third of people with advanced cancer who experience nausea and vomiting will require more than one anti-emetic to control their nausea and vomiting.</li></ul></li></ul></li><li>Refer to a specialist palliative care team if symptoms remain uncontrolled after 24 hours.</li></ul><!-- end field 92e74ea3-406b-4513-9736-349baccdcefd --><!-- end item 4d9090a3-bf11-48b5-98ef-b1bd5aaa6d18 -->","subChapters":[{"id":"56ecbfd8-cee3-532a-a6fe-2f7c48731a8b","slug":"basis-for-recommendation-b91","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 2c9afd0f-4258-4088-9071-9baabf471333 --><h4>Basis for recommendation</h4><!-- end field 2c9afd0f-4258-4088-9071-9baabf471333 -->","summary":null,"htmlStringContent":"<!-- begin item b911d4e2-4d2d-41b6-b57c-2a9d98e14cfd --><!-- begin field 498e0447-54b8-4458-82f0-8b525eb0e4c9 --><p>These are pragmatic recommendations based on expert opinion from current literature [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">Perdue, 2005</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">Twycross et al, 2009</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">Ang et al, 2010</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">Lothian Palliative Care Guidelines Group, 2010</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">Twycross, 2014</a>] and from CKS expert reviewers.</p><ul><li>Prokinetics should not be used concurrently with drugs with antimuscarinic activity (for example cyclizine, hyoscine) because antimuscarinic drugs competitively block the action of prokinetics [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">Lothian Palliative Care Guidelines Group, 2010</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">Twycross, 2014</a>].</li><li>CKS are aware that the European Medicines Agency (EMA) has issued advice restricting the use of metoclopramide and domperidone [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">EMA, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">European Medicines Agency, 2014</a>]. Following clarification from the EMA this advice does not apply to unlicensed uses of metoclopramide (for example palliative care) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-nausea-vomiting/references/\">BNF 72, 2016</a>].</li></ul><!-- end field 498e0447-54b8-4458-82f0-8b525eb0e4c9 --><!-- end item b911d4e2-4d2d-41b6-b57c-2a9d98e14cfd -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}